Jiangsu Ke Feiping Pharmaceutical

Ke Feiping Pharmaceutical is a Chinese biopharmaceutical company focused on the research, development, and commercialization of innovative small molecule therapeutics. The company specializes in gastrointestinal, cardiovascular, and cerebrovascular diseases, with a strong emphasis on acid-related disorders. Its lead product, Keverprazan (KFP-H008), is a novel potassium-competitive acid blocker (P-CAB) developed in China and approved for the treatment of duodenal ulcers. Ke Feiping operates an integrated business model that includes a modern manufacturing base and an extensive domestic sales network. Founded in 2006 and headquartered in Nanjing, the company has successfully transitioned from a pharmaceutical distributor to an innovation-driven drug developer.